See more : MKVENTURES CAPITAL LIMITED (MKVENTURES.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Big Cypress Acquisition Corp. (BCYP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Big Cypress Acquisition Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- A.D.Works Group Co.,Ltd. (2982.T) Income Statement Analysis – Financial Results
- First Foundation Inc. (FFWM) Income Statement Analysis – Financial Results
- Afarak Group Oyj (AFAGR.HE) Income Statement Analysis – Financial Results
- Kumho Tire Co., Inc. (073240.KS) Income Statement Analysis – Financial Results
- Waaree Energies Ltd (WAAREEENER.NS) Income Statement Analysis – Financial Results
Big Cypress Acquisition Corp. (BCYP)
About Big Cypress Acquisition Corp.
Big Cypress Acquisition Corp. intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It intends to focus on life science companies in the United States and Israel. The company was founded in 2020 and is based in Miami Beach, Florida.
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | 0.00 | 3.44M |
| Cost of Revenue | 0.00 | 0.00 |
| Gross Profit | 0.00 | 3.44M |
| Gross Profit Ratio | 0.00% | 100.00% |
| Research & Development | 0.00 | 8.02M |
| General & Administrative | 0.00 | 4.10M |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 0.00 | 4.10M |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 0.00 | 12.12M |
| Cost & Expenses | 0.00 | 12.12M |
| Interest Income | 26.13K | 113.13K |
| Interest Expense | 0.00 | 428.48K |
| Depreciation & Amortization | 548.18K | 323.41K |
| EBITDA | 0.00 | -8.23M |
| EBITDA Ratio | 0.00% | -239.25% |
| Operating Income | 0.00 | -8.67M |
| Operating Income Ratio | 0.00% | -252.01% |
| Total Other Income/Expenses | 0.00 | -312.75K |
| Income Before Tax | 0.00 | -8.99M |
| Income Before Tax Ratio | 0.00% | -261.09% |
| Income Tax Expense | 0.00 | 115.73K |
| Net Income | 0.00 | -8.99M |
| Net Income Ratio | 0.00% | -261.09% |
| EPS | 0.00 | -0.21 |
| EPS Diluted | 0.00 | -0.21 |
| Weighted Avg Shares Out | 43.47M | 43.47M |
| Weighted Avg Shares Out (Dil) | 43.47M | 43.47M |
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #ACTG--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that an independent Data Safety Monitoring Board...
Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics
MIAMI, Sept. 23, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that it will hold a Special Meeting of stockholders (the "Special Meeting") to,...
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BARDA--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that the U.S. Department of Defense (DoD)...
SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BCYP--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completion of enrollment in its Phase...
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BCYP--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics without the need for human donors, today announced the publication of data showing that...
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics, today announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will present at the Ladenburg...
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #COVID19--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics, today announced the publication of in vitro data showing that SAB-185, the company's therapeutic...
Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination with SAB Biotherapeutics
MIAMI, July 7, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a blank check company focused on innovative biopharmaceutical firms, today announced the confidential submission with the U.S. Securities and Exchange Commission ("SEC") of a draft registration statement...
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases
SIOUX FALLS, S.D. & MIAMI--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces targeted, high potency, fully-human polyclonal antibodies at scale, and Big Cypress Acquisition Corp. (NASDAQ: BCYP), a blank check company focused on...
Source: https://incomestatements.info
Category: Stock Reports